GlassScriptPhysician profile
Fazal Panezai
NPI 1710069760
$1,694.59
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $527 · 2021: $527 · 2022: $407 · 2023: $13.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $433.06 | 2019-2021 | |
| Glaxosmithkline, LLC. | $347.39 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $211.68 | 2020-2022 | |
| Pfizer INC. | $204.83 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $132.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.12 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $52.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.23 | 2019 | |
| Novo Nordisk INC | $27.81 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.50 | 2022 | |
| Amgen INC. | $25.24 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.59 | 2022 | |
| Antares Pharma, INC. | $14.56 | 2022 | |
| Lifescan, INC. | $14.20 | 2022 | |
| Acadia Pharmaceuticals INC | $14.02 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.98 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.98 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.84 | 2021 | |
| Horizon Therapeutics Plc | $13.22 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fazal Panezai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.